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Abstract
Background: Nephropathic cystinosis is an autosomal recessive disorder resulting in an impaired transport of
cystine trough the lysosomal membrane causing an accumulation of free cystine in lysosomes. The only specific
treatment for nephropathic cystinosis is cysteamine bitartrate. This study was aimed to describe the relationship
between cysteamine plasma concentrations and white blood cell cystine levels, and to simulate an optimized
administration scheme to improve the management of patients with cystinosis.
Methods: Cysteamine and cystine concentrations were measured in 69 nephropathic cystinosis patients. A total of
250 cysteamine plasma concentrations and 243 intracellular cystine concentrations were used to perform a
population pharmacokinetic and pharmacodynamic analysis. An optimized administration scheme was simulated in
order to maintain cystine levels below 1 nmol half-cystine/mg of protein and to investigate the possibility of
administrating the treatment less than 4 times a day (QID, recommended). The current dosing recommendations
are 1.3 g/m
2/day for less than 50 kg BW and 2 g/day thereafter; the maximum dose should not exceed 1.95 g/m
2/
day.
Results: Cysteamine concentrations were satisfactorily described by a one-compartment model. Parameter
estimates were standardized for a mean standard bodyweight using an allometric model. WBC cystine levels were
adequately described by an indirect response model where the first-order removal rate constant is stimulated by
the cysteamine concentrations.
Conclusions: According to simulations, in order to increase the percentage of patient with cystine levels below 1
nmol half-cystine/mg of protein, the current dosages could be changed as follows: 80 mg/kg/day (QID) from 10 to
17 kg, 70 mg/kg/day (QID) from 17 to 25 kg, 60 mg/kg/day (QID) from 25 to 40 kg and 50 mg/kg/day (QID) from
40 to 70 kg (these dosages remain under the maximum recommended dose). However an 8-hourly daily treatment
(TID) did not provide acceptable cystine levels and should not be proposed.
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Background
Nephropathic cystinosis is an autosomal recessive disor-
der resulting in an impaired transport of cystine trough
the lysosomal membrane causing an accumulation of
free cystine in lysosomes [1]. Lysosomal cystine accumu-
lation leads to the formation of intracellular crystal
throughout the body. The kidney is the most damaged
organ, leading to progressive renal failure. Without spe-
cific therapy, end stage renal failure occurs before 10
years of age [2]. Patients with cystinosis suffer addition-
ally from severe growth retardation and photophobia
due to the accumulation of cystine crystals in the cornea
[1].
T h eo n l ys p e c i f i ct r e a t m e n tfor nephropathic cystino-
sis is cysteamine bitartrate (Cystagon
®) which has chan-
ged the course of the disease. Treatment reduces the
progression of renal impairment and is more effective
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any medium, provided the original work is properly cited.when initiated before 2 years old when renal function is
still normal [3]. It is recommended to continue cystea-
mine treatment in patient with nephropathic cystinosis
after renal transplantation to limit cystine accumulation
in extra-renal tissues.
Limited studies are available on the pharmacokinetics
and pharmacodynamics of cysteamine, most of them
involving healthy adult subjects or a very small number
of pediatric patients [4-6]. Cysteamine bitartrate is
usually administered orally every 6 hours. The current
recommendations are 1.3 g/m
2/day for children less
than 50 kg, and 2 g/day thereafter. The dose of cystea-
mine should not exceed 1.95 g/m
2/day, the maximum
dose used in clinical trials [3].
In the present study, we have developed a population
pharmacokinetic model for cysteamine bitartrate in a
large group of nephropathic cystinosis patients from
children to adult in order to determine the relationship
between cysteamine plasma concentration and white
blood cell (WBC) cystine levels. Using this model, an
optimized administration scheme is suggested to main-
tain cystine levels below 1 nmol half-cystine/mg of
protein.
Methods
Patients and treatment
The population comprises 69 nephropathic cystinosis
patients, ranging in age from 0.4 to 36 years (mean 12.5
years), and in bodyweight from 7.6 to 83 kg (mean 34.3
kg). Patients received cysteamine bitartrate as capsule
every 6 hours for the treatment of nephropathic cystino-
sis, the mean (standard deviation) cysteamine dose was
35.5 (21) mg.kg
-1/day.
Study design
13 cystinotic patients ranging in age from 2.5 to 28
years and in bodyweight from 13.7 to 80.2 kg on cystea-
mine bitartrate were involved in an open-label study, at
steady state. The study consisted of collecting blood
samples from non-transplant patients receiving cystea-
mine before dose and 2, 3, 4, and 6 h after administra-
tion. These samples were used for plasma cysteamine
concentration assay and for WBC cystine concentration
assays.
On the other hand, 56 patients ranging in age from
0.4 to 36 years and in bodyweight from 7.6 to 83 kg
were involved in a monitoring routine basis.
Analytical method
Sample collection
Venous blood samples were collected into citric acid-
citrate-dextrose (ACD) tubes. For the monitoring of
treatment with cysteamine, samples were collected 6
hours post-dose. Whole blood was conserved at room
temperature until the sample was prepared. The plasma
was separated from the leucocytes and erythrocytes by
centrifugation at 1200 g for 15 min. The plasma layer
was collected and stored at -20°C until analysis of
cysteamine. The middle fraction containing total leuco-
cytes was collected and PMN cells were isolated accord-
ing to guidelines from the group “Cystine in white
blood cells” [7].
Determination of cysteamine
Cysteamine was determined as total cysteamine, by
liquid chromatography-MS/MS.
Sample preparation was carried out by adding 10 μlo f
internal standard (d4-deutered cysteamine) 100 μM, 10
μL of DTT 0.1 M for reduction of disulfide bond to 200
μl of plasma. After incubation at 37°C for 15 min, 30 μL
of 12% sulfosalicylic acid was added to deproteinize the
sample. After centrifugation, 20 μlo f5 . 2m MN - e t h y l -
maleimide (NEM) was added. 5 μL was then injected
into LC-MS/MS. Chromatographic separation was
achieved on an Agilent 1100 system (Agilent Technolo-
gies, Waldbronn, Germany) using a XD8-C8 column
(150 × 4.6 mm, reference UP3OD#3QS; Interchim). The
c o l u m nw a se l u t e da t6 0 0μl/min using an isocratic
mobile phase of water/acetonitrile (410/90) with 0.1%
formic acid.
The column eluate was injected directly into the
Applied Biosystems/MDS Sciex API3000 MSMS which
was maintained in an electrospray positive mode.
Determination of cystine
PMN cells cystine levels, reported as nmol half-cystine/
mg protein were measured using liquid chromatogra-
phy-tandem mass spectroscopy (API 3000LC/MS/MS;
Applied Biosystems/MDS Sciex) with previously
described methods [8].
Modeling strategy and population pharmacokinetic-
pharmacodynamic model
Data were analysed using the nonlinear mixed effect
modelling software program Monolix version 31s http://
wfn.software.monolix.org[9]. Parameters were estimated
by computing the maximum likelihood estimator of the
parameters without any approximation of the model (no
linearization) using the stochastic approximation expec-
tation maximization (SAEM) algorithm combined to a
MCMC (Markov Chain) monte Carlo) procedure. The
number of MCMC chains was fixed to 5 for all estima-
tions. The between-subject variabilities (BSV or h) were
ascribed to an exponential model. Parameter shrinkage
was calculated as {1-sd(eta)/omega}, where sd(eta) and
omega are the standard deviation of individual eta para-
meters and the population model estimate of the BSV
respectively [10]. The Likelihood Ratio Test (LRT)
including the log-likelihood, the Akaike information cri-
terion (AIC) and the bayesian information criterion
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the final model, covariate effect(s) on pharmacokinetic
parameter(s), residual variability model (proportional
versus proportional plus additive error model), and
structure of the variance-covariance matrix for the BSV
parameters.
Main covariates of interest in the population were age,
bodyweight (BW), creatinine clearance, size, and body
surface area (BSA).
Pharmacokinetics parameter estimates were standar-
dized for a mean standard bodyweight using an allo-
metric model: Pi =P STD × (BWi/BWSTD)
PWR
Where PSTD is the standard value of parameter for a
patient with the standard bodyweight value and Pi and
BWi are the parameter and bodyweight of the ith indivi-
dual. The PWR exponents may be estimated from the
data. However, from allometric scaling theory these are
typically 0.75 for clearance parameters and 1 for
volumes of distribution [11].
For evaluation of the goodness-of-fit, the following
graphs were performed for the final model: observed
and predicted concentrations versus time, observed con-
centrations vs population predictions, weighted residuals
vs time and weighted residuals vs predictions. Similar
graphs using individual predictive estimation were
examined. Diagnostic graphics were obtained using the
R program [12].
The pharmacokinetic parameters were then fixed and
the parameters of the pharmacodynamic model were
estimated. An indirect response model with a zero-order
production rate constant (Kin) and a first-order removal
rate constant (Kout) was used to describe the WBC
cystine levels. Cysteamine stimulates the first-order
removal rate constant to allow the cystine depletion
according to the following equation:
dR
dt
=K in − Kout .

Emax .C P
EC50 +C P

× R
where R is the pharmacodynamic response, Emax is the
maximum effect, Cp is the cysteamine concentration,
EC50 is the concentration producing 50% of maximal
response. Kin is derived from Kout and Ro, baseline, as
Kin =K out × Ro. A simultaneous pharmacokinetic-phar-
macodynamic modeling was then performed to estimate
both pharmacokinetic and pharmacodynamic
parameters.
Visual predictive check (VPC) validation
Cysteamine and cystine concentration profiles were
simulated and compared with the observed data to eval-
uate the predictive performance of the model. Simulated
concentrations were then compared with the observed
data to evaluate the predictive performance of the
model. The vector of pharmacokinetic parameters was
simulated using the final model. Each vector parameter
was drawn in a log-normal distribution with a variance
corresponding to the BSV previously estimated. A simu-
lated residual error was added to each simulated con-
centration. All observed and simulated concentrations
were standardized for a cysteamine bitartrate dose of
600 mg/day. The 5
th,5 0
th and 95
th percentiles of the
simulated concentrations at each time were then over-
laid on the observed concentration data and a visual
inspection was performed. The variability was reason-
ably estimated if the 95% confidence interval for the
proportion of observed data outside the bounds
included the theoretical value of 10%.
Doses simulations
To propose doses in mg/kg not exceeding the maximum
dose of 1.95 g/m
2/day, the following formula for the
pediatric population: BSA = [(4 × BW) + 7]/(BW + 90)
(Additional information can be found at the “Société
Francophone de Médecine d’Urgence”, website http://
www.sfmu.org/fr/formation/calculateurs#Pediatrie) was
used to represent the maximum cysteamine dose in mg/
kg as a function of bodyweight. Different doses per kilo-
gram per day in function of bodyweight were then
derived. The current recommendations as well as our
derived daily doses were simulated for a TID and for a
QID administration; the percentage of patient achieving
WBC cystine levels below 1 or below 2 nmol half-
cystine/mg of protein was then calculated and the
cystine levels associated were drawn.
Results
Demographic data
250 cysteamine plasma concentrations and 243 intracel-
lular cystine concentrations from 69 patients were avail-
able for pharmacokinetic and pharmacodynamic
evaluation. The median cysteamine bitartrate daily dose
administered 4 times a day was 1 g ranging from 200
mg to 2.7 g. Table 1 summarizes patients’
characteristics.
Table 1 Characteristics of the nephropathic cystinosis
patients (n = 69) enrolled in the pharmacokinetics and
pharmacodynamics study.
Mean Min-Max
Age (years) 12.5 0.4 - 36
Weight (kg) 34.3 7.6 - 83
Creatinine levels (μmol/L) 125.2 24 - 800
Creatine clearance (ml/min) 88.6 6.4 - 172.5
Taille (cm) 127.4 67 - 177
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A one-compartment model adequately described the
data, thus the apparent parameters of the model were
the clearance (CL/F), the volume of distribution (V/F),
and the absorption rate constant (Ka), F is the unknown
bioavailability. Residual variability was best described by
a proportional error model. Inter-subject variability was
described by exponential error model and retained only
for apparent clearance. The allometric scaling of clear-
ance (CL/F) and volume term (V/F) improved the good-
ness of fit. None of the other covariates (age, creatinine
clearance, size, BSA) had a significant effect on the
model. Figure 1(A) displays cysteamine observed and
predicted plasma concentrations as a function of time.
Table 2 summarizes the final population pharmacoki-
netic estimates. All the parameters were well estimated,
given their relative standard error (RSE%). The h-shrinkage
for CL/F was 0.13 indicating that the empirical Bayesian
estimates for individual clearance parameter are reliable.
WBC cystine levels
An indirect response model where the first-order
removal rate constant (kout) is stimulated by the cystea-
mine concentrations adequately described the data. Resi-
dual variability was best described by a proportional
error model. The inter-subject variability was described
by exponential error model and retained only for base-
line (predose) cystine level (Ro). Figure 1(B) displays
WBC cystine levels observed and predicted concentra-
tions as a function of time for the patients. Table 2
summarizes the final population pharmacodynamic esti-
mates. All the parameters were well estimated, given
their relative standard error (RSE%). The h-shrinkage
for Ro was 0.15 indicating that the empirical Bayesian
estimates for individual baseline parameter are reliable.
Figure 1(C) displays the cysteamine predicted plasma
concentrations and WBC cystine levels predicted con-
centrations as a function of time for an administration
of 600 mg/day.
Evaluation and validation
Figure 2 (VPC) shows that the average prediction matches
the observed concentration time-courses and that the
variability is reasonably estimated. The number
Figure 1 (A) Observed cysteamine concentrations (o) and
population predicted cysteamine concentrations (curve) as a
function of time in log scale; (B) Observed WBC cystine levels
(o) and population predicted cystine concentrations (curve) as
a function of time.
Table 2 Population pharmacokinetic and
pharmacodynamic parameters of WBC cystine levels and
cysteamine standardized for a weight of 70 kg.
Parameters Mean RSE (%)
Structural pharmacokinetic model
ka (h
-1) 1.38 7
V/F (L/70 kg) 82.4 11
CL/F (L/h/70 kg) 42.3 8
Statistical pharmacokinetics model
ωCL/F 0.28 10
s 0.45 5
Structural pharmacodynamic model
Ro (nmol half-cystine/mg of protein) 1.59 9
Kout (h
-1) 20.2 33
Emax 3.82 7
EC50 (μmol/L) 12.5 15
Statistical pharmacodynamic model
ωRo 0.62 11
s 0.49 5
Key: RSE%, relative standard error (standard error of estimate/estimate*100),
Ka absorption rate constant, CL/F apparent elimination clearance, V/F
apparent volume of distribution, Ro baseline (predose) cystine level, Kout first-
order removal rate constant, Emax maximum stimulation of Kout,E C 50
concentration resulting in 50% of maximal response, s residual variability
estimates, ω interindividual variability estimates. The typical parameters refers
to an adult patient weighing 70 kg according to an allometric model: [Typical
value] = [Typical parameter] * (bodyweight/70)
PWR where PWR = 0.75 for CL
and 1 for V.
Figure 2 Evaluation of the final model: comparison between
the 5th, 50th and 95
th percentile obtained from 400
simulations (lines), and the observed data (o) for cysteamine
concentrations standardized for a cysteamine dose of 900 mg/
day (A) and for WBC cystine levels (B).
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interval was for plasma cyteamine concentrations 232/250
(92.8%) and for WBC cystine levels 225/243 (92.5%).
Doses simulations
Figure 3 shows the maximum cysteamine dose recom-
mended and the usual recommendations as a function
of bodyweight. Without exceeding the maximum recom-
mended dose, increased doses could be provided as fol-
lows: 80 mg/kg/day from 10 to 17 kg, 70 mg/kg/day
from 17 to 25 kg, 60 mg/kg/day from 25 to 40 kg and
50 mg/kg/day from 40 to 70 kg. Figure 4 displays the
percentage of patient as a function of bodyweight with
cystine levels below 1 and 2 nmol half-cystine/mg of
protein with the usual recommendation, and with our
proposed daily dose given 4 times a day or 3 times a
day. Our daily dose proposition given 4 times a day led
to a higher percentage of patient achieving satisfactory
cystine levels from 10 to 70 kg.
However the percentage of patient achieving cystine
levels below 1 and 2 nmol half-cystine/mg of protein
with our daily dose proposal given 3 times a day
remains very low and should not be proposed to
patients.
The simulated profile of WBC cystine levels associated
with the usual recommendation and with our proposed
daily dose given 4 times a day or 3 times a day was then
performed according to the bodyweight groups (10 to
17 kg, 17 to 25 kg, 25 to 40 kg, and 40 to 70 kg) defined
by our dosing schedules (Figure 5). Our four daily doses
appear to decrease in each group of bodyweight cystine
levels compared to the usual recommendation. Never-
theless, our three daily doses did not provide satisfactory
cystine levels.
Table 3 provides cysteamine residual concentrations
according to bodyweight groups derived from the cur-
rent recommendations and these study recommenda-
tions. With the current recommendations, the residual
Figure 3 Daily dose (mg/kg/day) of cysteamine as a function of
bodyweight. The red line corresponds to the maximum daily dose
recommended. The blue line corresponds to the usual daily dose
recommended. Black arrows correspond to study daily dose
recommendations.
Figure 4 Percentage of patients with cystine concentrations below 1 nmol half-cystine/mg of protein (dashed lines) or below 2 nmol
half-cystine/mg of protein (lines) according to bodyweight for the usual recommendations and for our dosing scheme (mg/kg/day)
administered either in QID regimen or TID regimen.
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cystine levels were significantly higher in each body-
weight groups compared to patients with no satisfactory
cystine levels (more than 2 nmol half-cystine/mg of pro-
tein). The residual cysteamine concentrations derived
from this study recommendations were closed to those
obtained in patients with low cystine levels treated with
the current recommendations. Thus, cysteamine residual
concentrations could be monitored instead of cystine
levels (easier in practical terms) and propose our four
daily dosing scheme instead of the current
recommendations at least for patients with low values of
residual cysteamine plasma concentration according to
the corresponding bodyweight group (table 3).
Discussion
Cystinosis is an inherited disorder characterized by
defected lysosomal efflux of cystine causing a continu-
ous accumulation of free cystine and intracellular crystal
formation across the body. Without any treatment cysti-
nosis progresses to renal failure. The therapeutic
approach for cystinotic patients consists of cysteamine
Figure 5 Simulated cystine median (lines) and IC90 (dashed lines) concentrations (nmol half-cystine/mg of protein) according to
bodyweight groups for the usual recommendations and for our dosing scheme (mg/kg/day) administrated either in QID regimen or
TID regimen.
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in the depletion of intracellular cystine [1]. This paper
describes the pharmacokinetics and the pharmacody-
namics of cysteamine in 69 cystinotic patients aged 5
months to 36 years. Cysteamine concentrations were
satisfactorily described by a one compartment model. In
our model, no effect of age on clearance was observed
following the bodyweight-based allometric scaling of the
parameters. Creatinine clearance did not have an influ-
ence on the pharmacokinetic parameters which can be
explained by the limited number of patients with severe
renal insufficiency involved in the study; indeed, some
data suggest that cysteamine pharmacokinetic para-
meters may not be significantly modified in patients
with mild to moderate renal insufficiency [3]. One the
other hand cysteamine is mainly eliminated via metabo-
lism pathway.
To be effective, cysteamine has to pass through lyso-
somal membranes where it reacts with cystine to form a
cysteine-cysteamine complex which can be depleted
from the lysosome using the lysine transport system
[13]. With respect to the mechanism of action of cystea-
mine, an indirect response model was used to describe
the WBC cystine concentrations. Cystine was repre-
sented as an effect compartment with a zero-order pro-
duction rate constant (Kin) and a first-order removal
rate constant (Kout). To reproduce the cystine depletion
caused by cysteamine a model where the drug concen-
tration stimulates the exit constant (Kout) was used. This
model describes satisfactorily the link between cystea-
mine concentrations and WBC cystine levels. The thera-
peutic aim of the treatment of cystinosis is to maintain
WBC cystine levels lower than 1 nmol half-cystine/mg
of protein. At present, the rhythm of administration of
cysteamine bitartrate is 4 times a day which is uncomfo-
table and may cause non-compliance. According to the
model we simulated an optimized administration
scheme which decreases the administration rhythm
while maintaining cystine levels below 1 nmol half-
cystine/mg of protein. It appears that the every 6-hourly
daily treatment with cysteamine bitartrate could not be
decreased to an 8-hourly daily treatment without
exceeding the recommended maximum daily dose (1.95
g/m
2/day used in clinical trials). However, the current
recommended 6-hourly daily treatment could be
improved by increasing the percentage of patient with
satisfactory cystine levels (below 1 or 2 nmol half-
cystine/mg of protein) which could be a way to improve
the management of patients with cystinosis. Our model-
ing was based on data with 95% of the children weigh-
ing between 12 and 70 kg, thus to avoid risks of
extrapolation from the model, our recommendation was
based on a range from 10 to 70 kg.
Conclusion
This study reports cysteamine pharmacokinetics and
pharmacodynamics in nephropathic cystinosis patients.
A model linking the cysteamine concentrations to the
WBC cystine levels was performed. According to this
model a dosing scheme not exceeding the maximum
recommended daily dose was simulated to improve the
cystine concentrations profile obtained with usual
recommendation. According to the simulations, nephro-
pathic cystinosis patients should receive the following
cysteamine bitartrate dose: 80 mg/kg/day (QID) from 10
to 17 kg, 70 mg/kg/day (QID) from 17 to 25 kg, 60 mg/
kg/day (QID) from 25 to 40 kg and 50 mg/kg/day (QID)
from 40 to 70 kg. To limit the risk of drug toxicity, the
starting dose of cysteamine should be 1/4 to 1/6 of the
scheduled maintenance dose and progressively increased
by 10 mg/kg increments every two weeks until the final
dose is achieved [3]. However an 8-hourly daily treat-
ment could not be proposed with regard to the maxi-
mum recommended daily dose of 1.95 g/m
2/day.
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Table 3 Residual cysteamine (6-hour post-dose) concentrations (μmoL/L) obtained with current recommendations and
this study recommendations according to bodyweight groups.
Residual cysteamine concentration (μmoL/L) median (sd)
WT Current Recommendations Study recommendations
Patients with cystine > 2 Patients with cystine < 2 pvalue
10-17 kg 1.7 (2.8) 4.8 (5.7) <1 0
-4 4.3 (7.0)
17-25 kg 2.1 (4.0) 6.1 (7.3) <1 0
-4 5.4 (9.2)
25-40 kg 2.6 (3.9) 6.4 (7.6) <1 0
-4 6.5 (9.4)
40-70 kg 3.3 (4.5) 7 (7.9) <1 0
-4 7.9 (10.6)
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